WHO ICTRP trial
Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell…
JPRN-jRCT2071200071 · Japan Primary Registries Network (JPRN) · Recruiting
Key facts
| Trial ID | JPRN-jRCT2071200071 |
|---|---|
| Public title | Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplant |
| Scientific title | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Ravulizumab in Adult and Adolescent Participants who have Thrombotic Microangiopathy (TMA) after Hematopoietic Stem Cell Transplant (HSCT) |
| Primary sponsor | Yokosawa Jun |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Phase | 3 |
| Countries | North America;Japan;France;Japan;Italy;Japan;Belgium;Japan;South Korea;Japan;Spain;Japan;Canada;Japan |
| Conditions | Thrombotic Microangiopathy (TMA) after Hematopoietic Stem Cell Transplantation (HSCT) Thrombotic Microangiopathy TMA;Thrombotic Microangiopathy TMA |
| Interventions | The ravulizumab will be administered via IV infusion as below dosage regimen; In cae Patient Body Weight (kg) is 30 to 40, 1200mg at Day1, 300mg at at Day5 and Day10 and 2700mg at every 8 weeks after Day15 In cae Patient Body Weight (kg) is… |
| Registration date | Dec 21, 2020 |
| Target size | 184 |
| Secondary IDs | NCT04543591 |
| Registry page | jrct.niph.go.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: